Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients

This study has been completed.
Beijing Fresenius Kabi Pharmaceutical Co
Information provided by (Responsible Party):
Xue Qing Yu, Sun Yat-sen University Identifier:
First received: August 11, 2010
Last updated: May 20, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2013
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)